BUSINESS

Daiichi Sankyo Grabs Europe Rights to 1st-in-Class Cholesterol Drug

January 8, 2019
Daiichi Sankyo has earned exclusive rights to commercialize US upstart Esperion Therapeutics’ first-in-class hypercholesterolemia treatment bempedoic acid and its combination pill with ezetimibe in European countries. The Japanese drug major said on January 7 that it entered into a licensing…

To read the full story

BUSINESS

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…